1. Non-Smad TGF-β Signaling Components are Possible Biomarkers of Tamoxifen Resistance.
- Author
-
Babyshkina, N., Zavyalova, M., Patalyak, S., Dronova, T., Slonimskaya, E., and Cherdyntseva, N.
- Subjects
ESTROGEN receptors ,STEROID receptors ,PROTEIN-tyrosine kinases ,PROTEIN kinases ,TRANSFORMING growth factors - Abstract
A crosstalk between the estrogen receptor alpha (ERα) and tyrosine kinase receptors contribute to endocrine resistance. We investigated the effect of the four Smad-independent TGF-β signaling components and the distribution pattern of ERα expression on the response to adjuvant tamoxifen treatment in 122 estrogen positive breast cancer patients. We identified a low mRNA expression of TGF-βR1 in tamoxifen resistant group patients (TR) in contrast to tamoxifen sensitive group (TS). Similarly, negative TGF-βR1 expression was significantly higher in TR patients than in TS patients. The expression of TGF-βR1 was strongly correlated with the distribution pattern of ERα expression, level of CD44
+ /CD24-low cells and Akt (pS473) expression. The patients with a low mRNA expression of TGF-βR1 as well as with a negative TGF-βR1 expression had an unfavorable prognosis concerning progression-free survival. The expression of TGF-βR1 and the distribution pattern of ERα expression can be considered as additional molecular predictive markers for estrogen positive breast cancer patients treated with adjuvant tamoxifen. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF